Cancer Research and Treatment

Original Articles

Breast cancer

Marked Reduction in the Risk of Dementia in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study: Jooyoung Oh, Hye Sun Lee, Soyoung Jeon, Jeong-Ho Seok, Tae-Kyung Yoo, Woo-Chan Park, Chang Ik Yoon; Cancer Res Treat. 2023;55(2):551-561. Published online October 19, 2022; DOI: https://doi.org/10.4143/crt.2022.272

Abstract PDF Supplementary Material PubReader ePub

Purpose
An inverse relationship between cancer and neurodegenerative disease, which presents the possibility of a reduced risk of dementia in cancer patients, has been suggested previously. However, a nationwide longitudinal population-based study of specific types of cancer with due consideration of treatment effects has not been conducted.
Materials and Methods
This nationwide population-based cohort study used data obtained in a 12-year period (January 2007- December 2018) in the Korean National Health Insurance claims database. All female breast cancer patients (age ≥ 50 years) diagnosed between 2009 and 2010 were included after excluding those with physician visits for any cancer during a 2-year period (2007-2008). Patients with senile cataract constituted the control group. The main study outcome was the risk of developing dementia.
Results
From a total of 90,396 and 85,906 patients with breast cancer and cataract, respectively, patients without behavior codes were excluded. Data for 15,407 breast cancer patients and 7,020 controls were analyzed before matching. After matching for comorbidities and age, either group comprised 2,252 patients. The median follow-up time was 104.1±24.0 months after matching. After matching, breast cancer was a predictor of a lower risk of for dementia (hazard ratio, 0.091; 95% confidence interval, 0.075 to 0.111; p < 0.001). In breast cancer patients, receiving chemotherapy and endocrine therapy did not significantly affect the incidence of dementia.
Conclusion
Breast cancer was associated with a remarkably decreased risk of dementia. The findings strongly suggest an inverse relationship between cancer and neurodegeneration, regardless of the adverse effects of cancer treatment on cognitive function.

Citations

Citations to this article as recorded by

Timing of risk factors, prodromal features, and comorbidities of dementia from a large health claims case–control study
Stefan Teipel, Manas Akmatov, Bernhard Michalowsky, Steffi Riedel-Heller, Jens Bohlken, Jakob Holstiege
Alzheimer's Research & Therapy.2025;[Epub] CrossRef
Bidirectional association between breast cancer and dementia: a systematic review and meta-analysis of observational studies
Fuxing Bao, Liang Yu, Xiaolei Zhang, Qier Mu
PeerJ.2025; 13: e18888. CrossRef
Changes in the Emergency Department Visits Among the Older Adults With Dementia Before, and After the Nationwide Social Distancing Measures: An Interrupted Time Series Analysis
Jeongmin Moon, Kyung‐Shin Lee, Ho Kyung Sung, Seonji Kim
International Journal of Geriatric Psychiatry.2025;[Epub] CrossRef
Association between Benzodiazepine and Dementia Risk in Treating Depression after Breast Cancer Diagnosis: A Nationwide Population-Based Cohort Study
Taehwan Kim, Hye Sun Lee, Soyoung Jeon, Dooreh Kim, Eunjoo Kim, Woo-Chan Park, Chang Ik Yoon, Jooyoung Oh
Yonsei Medical Journal.2025; 66(9): 564. CrossRef
Cardiovascular contributions to dementia: Examining sex differences and female‐specific factors
Madeline Wood Alexander, Jane Paterson, Zoe Arvanitakis, Sandra E. Black, Kaitlin B. Casaletto, Marie K. Christakis, Gillian Einstein, Liisa A. M. Galea, Leila Harwood, Amy Kirkham, Sara Mitchell, Judy Pa, Lucas Perri, Tallinn F. L. Splinter, Walter Sward
Alzheimer's & Dementia.2025;[Epub] CrossRef
Alzheimer Disease in Breast Cancer Survivors
Su-Min Jeong, Wonyoung Jung, Hyeonjin Cho, Hea Lim Choi, Keun Hye Jeon, Ki-Woong Nam, Yun-Gyoo Lee, Bongseong Kim, Kyungdo Han, Dong Wook Shin
JAMA Network Open.2025; 8(6): e2516468. CrossRef
The risk of dementia in breast cancer survivors: a meta-analysis of observational studies
Shijun Tan, Jiawei Yang, Guiping Guo, Shicui Hong, Li Guo, Honglin Situ
Annals of Medicine.2025;[Epub] CrossRef
Inverse association of cancer with diagnoses of dementia in a large health claims case-control study
Stefan Teipel, Manas Akmatov, Bernhard Michalowsky, Steffi Riedel-Heller, Christian Junghanss, Jakob Holstiege, Jens Bohlken
Journal of Alzheimer’s Disease.2025; 108(1): 98. CrossRef
Dementia and Cancer: Unravelling Methodological Biases in a Population-Based Cohort
Amber P. Selie, Kimberly D. van der Willik, M. Arfan Ikram, Jeremy A. Labrecque, Sanne B. Schagen
Neuroepidemiology.2025; : 1. CrossRef
Developing theragnostics for Alzheimer's disease: Insights from cancer treatment
Hyun-ju Lee, Hee-Jeong Choi, Yoo Joo Jeong, Yoon-Hee Na, Jin Tae Hong, Ji Min Han, Hyang-Sook Hoe, Key-Hwan Lim
International Journal of Biological Macromolecules.2024; 269: 131925. CrossRef

8,458 View
189 Download
11 Web of Science
10 Crossref

Hematologic malignancy

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study: Yu Ri Kim, Soo-Jeong Kim, Hye Sun Lee, Soyoung Jeon, Hyunsoo Cho, Haerim Chung, Ji Eun Jang, June-Won Cheong, Yoo Hong Min, Jin Seok Kim; Cancer Res Treat. 2022;54(2):613-620. Published online August 5, 2021; DOI: https://doi.org/10.4143/crt.2021.270

Abstract PDF PubReader ePub

Purpose
Event-free survival at 24 months (EFS24) is known to be a surrogate marker for overall survival (OS) for patients with peripheral T-cell lymphoma (PTCL). We examined the role of EFS24 in PTCL compared to diffuse large B-cell lymphoma (DLBCL), and then assessed the clinical predictive factors of achieving EFS24.
Materials and Methods
Patients with newly diagnosed PTCL treated with anthracycline-based chemotherapy were included. Subsequent OS was defined as the time elapsed from 24 months after diagnosis until death from any cause in those who achieved EFS24.
Results
Overall, 153 patients were evaluated, and 51 patients (33.3%) achieved EFS24. Patients who achieved EFS24 showed superior OS compared to patients who did not (p < 0.001). EFS24 could stratify the subsequent OS although it did not reach to that of the general population. After matching the PTCL group to the DLBCL group based on the international prognostic index, the subsequent OS in patients who achieved EFS24 was similar between the two groups (p=0.094). Advanced stage was a significant factor to predict the failing EFS24 by multivariable analysis (p < 0.001).
Conclusion
Patients with PTCL who achieve EFS24 could have a favorable subsequent OS. Since advanced disease stage is a predictor of EFS24 failure, future efforts should focus on developing novel therapeutic strategies for PTCL patients presenting with advanced disease.

Citations

Citations to this article as recorded by

Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas
Chu-Yi Chan, Tung-Liang Lin, Ming-Chung Kuo, Yu-Shin Hung, Hung Chang, Che-Wei Ou, Jin-Hou Wu, Hsuan-Jen Shih, Yi-Jiun Su, Lee-Yung Shih, Yuen-Chin Ong, Wen-Yu Chuang, Hsiao-Wen Kao
Annals of Medicine.2025;[Epub] CrossRef
Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS
Zheng Cao, Xiaojun Wang, Xuemin Xue, Xiaoli Feng
Annals of Hematology.2024; 103(3): 869. CrossRef
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments
Sarit Assouline, Adriana Wiesinger, Clare Spooner, Jelena Jovanović, Max Schlueter
Critical Reviews in Oncology/Hematology.2022; 175: 103711. CrossRef

8,801 View
146 Download
4 Web of Science
3 Crossref

First
Prev
Page of 1
Next
Last

Search